An Integrated Framework for Identifying Mutated Driver Pathway and Cancer Progression
暂无分享,去创建一个
[1] K. Plate,et al. p53 Mutations versus EGF Receptor Expression in Giant Cell Glioblastomas , 1997, Journal of neuropathology and experimental neurology.
[2] Kamran Ayub,et al. NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma , 2007, PLoS medicine.
[3] A. Nalla,et al. A novel approach to identify driver genes involved in androgen-independent prostate cancer , 2014, Molecular Cancer.
[4] D. Eisenberg,et al. Use of Logic Relationships to Decipher Protein Network Organization , 2004, Science.
[5] C. Sander,et al. Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.
[6] Benjamin J. Raphael,et al. Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.
[7] A. Ashworth,et al. Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.
[8] Teresa M. Przytycka,et al. MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types , 2015, Bioinform..
[9] Thomas Lengauer,et al. Mtreemix: a software package for learning and using mixture models of mutagenetic trees , 2005, Bioinform..
[10] Ruibin Xi,et al. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity , 2015, Oncotarget.
[11] R. Lothe,et al. The order of genetic events associated with colorectal cancer progression inferred from meta‐analysis of copy number changes , 2006, Genes, chromosomes & cancer.
[12] Tom H. Pringle,et al. The human genome browser at UCSC. , 2002, Genome research.
[13] Chitta Baral,et al. Joint learning of logic relationships for studying protein function using phylogenetic profiles and the rosetta stone method , 2006, IEEE Transactions on Signal Processing.
[14] Jack Kuipers,et al. pathTiMEx: Joint Inference of Mutually Exclusive Cancer Pathways and Their Progression Dynamics , 2017, J. Comput. Biol..
[15] Eli Upfal,et al. De Novo Discovery of Mutated Driver Pathways in Cancer , 2011, RECOMB.
[16] Christopher A. Miller,et al. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors , 2011, BMC Medical Genomics.
[17] Shi-Hua Zhang,et al. Discovery of co-occurring driver pathways in cancer , 2014, BMC Bioinformatics.
[18] Eli Upfal,et al. Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.
[19] Y. Yonekawa,et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. , 1996, Brain pathology.
[20] Junfeng Xia,et al. Identification of mutated driver pathways in cancer using a multi-objective optimization model , 2016, Comput. Biol. Medicine.
[21] Benjamin J. Raphael,et al. CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer , 2015, Genome Biology.
[22] Franziska Michor,et al. A Mathematical Methodology for Determining the Temporal Order of Pathway Alterations Arising during Gliomagenesis , 2012, PLoS Comput. Biol..
[23] E. E. Gresch. Genetic Alterations During Colorectal-Tumor Development , 1989 .
[24] Jingxuan Yang,et al. Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets , 2012, Cancer investigation.
[25] H. Greulich,et al. The genomics of lung adenocarcinoma: opportunities for targeted therapies. , 2010, Genes & cancer.
[26] Niko Beerenwinkel,et al. Identification of Constrained Cancer Driver Genes Based on Mutation Timing , 2015, PLoS Comput. Biol..
[27] Giancarlo Mauri,et al. Inferring Tree Causal Models of Cancer Progression with Probability Raising , 2013, bioRxiv.
[28] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[29] S. Vacher,et al. Differential Distribution of erbB Receptors in Human Glioblastoma Multiforme: Expression of erbB3 in CD133-Positive Putative Cancer Stem Cells , 2010, Journal of neuropathology and experimental neurology.
[30] J. P. Hou,et al. DawnRank: discovering personalized driver genes in cancer , 2014, Genome Medicine.
[31] Roded Sharan,et al. Simultaneous Identification of Multiple Driver Pathways in Cancer , 2013, PLoS Comput. Biol..
[32] E Premkumar Reddy,et al. Understanding the temporal sequence of genetic events that lead to prostate cancer progression and metastasis , 2013, Proceedings of the National Academy of Sciences.
[33] Lin Gao,et al. Detection of driver pathways using mutated gene network in cancer. , 2016, Molecular bioSystems.
[34] Benjamin J. Raphael,et al. Simultaneous Inference of Cancer Pathways and Tumor Progression from Cross-Sectional Mutation Data , 2015, J. Comput. Biol..
[35] Hao Wu,et al. Network-Based Method for Inferring Cancer Progression at the Pathway Level from Cross-Sectional Mutation Data , 2016, IEEE/ACM Transactions on Computational Biology and Bioinformatics.
[36] Rainer Storn,et al. Differential Evolution – A Simple and Efficient Heuristic for global Optimization over Continuous Spaces , 1997, J. Glob. Optim..
[37] D. Louis,et al. The retinoblastoma gene is involved in malignant progression of astrocytomas , 1994, Annals of neurology.
[38] Shi-Hua Zhang,et al. Efficient methods for identifying mutated driver pathways in cancer , 2012, Bioinform..
[39] E. Sprinzak,et al. Utilizing logical relationships in genomic data to decipher cellular processes , 2005, The FEBS journal.
[40] Niko Beerenwinkel,et al. Efficient sampling for Bayesian inference of conjunctive Bayesian networks , 2012, Bioinform..
[41] X. Hua,et al. DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. , 2013, American journal of human genetics.
[42] J. Uhm. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .
[43] J. Mora,et al. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression , 2016, Oncotarget.
[44] Hao Wu,et al. Identifying overlapping mutated driver pathways by constructing gene networks in cancer , 2015, BMC Bioinformatics.
[45] Alberto Orfao,et al. Amplified and Homozygously Deleted Genes in Glioblastoma: Impact on Gene Expression Levels , 2012, PloS one.
[46] D. Rubin,et al. Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .
[47] Gary D Bader,et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types , 2013, Scientific Reports.
[48] Giancarlo Mauri,et al. CAPRI: Efficient Inference of Cancer Progression Models from Cross-sectional Data , 2014, bioRxiv.
[49] C. D. Gelatt,et al. Optimization by Simulated Annealing , 1983, Science.
[50] Shihua Zhang,et al. Discovery of cancer common and specific driver gene sets , 2016, Nucleic acids research.
[51] A. Schäffer,et al. Graph models of oncogenesis with an application to melanoma. , 2001, Journal of theoretical biology.
[52] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[53] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[54] Jianxin Shi,et al. MEGSA: A powerful and flexible framework for analyzing mutual exclusivity of tumor mutations , 2015, bioRxiv.
[55] Niko Beerenwinkel,et al. Quantifying cancer progression with conjunctive Bayesian networks , 2009, Bioinform..
[56] Nicholas Eriksson,et al. The Temporal Order of Genetic and Pathway Alterations in Tumorigenesis , 2011, PloS one.
[57] Junhua Zhang,et al. The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms , 2016, IEEE/ACM Transactions on Computational Biology and Bioinformatics.
[58] C. Sander,et al. Automated Network Analysis Identifies Core Pathways in Glioblastoma , 2010, PloS one.